Vivus VVUS

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. What Arena's Belviq Television Ad Campaign Means For The Stock


      Mon, 14 Apr 2014

      By Spencer Osborne : The weight loss drug Belviq from Arena Pharmaceuticals ( ARNA ) is now being promoted on television with a national advertising campaign . This is a day that many long term investors have been waiting for. Can the emergence of a television ad campaign help sales of Belviq, and

    2. Arena - Belviq Sales Up Modestly Heading Into Television Ads


      Fri, 11 Apr 2014

      By Spencer Osborne : It is certainly an interesting time to be an investor in Arena Pharmaceuticals ( ARNA ). The company is about 10 months into its launch of the anti-obesity drug Belviq and the equity has taken several lumps along the way. The biggest challenges that Belviq faces are insurance

    3. Three Vivus directors won't stand for re-election


      Tue, 8 Apr 2014

      Vivus ( VVUS ) directors J. Martin Carroll, Robert N. Wilson, and Mark B. Logan ..... June 20 annual meeting. ( 8-K ) Carroll, Wilson, and Logan were all on Vivus ' board prior to the end of a bitter proxy fight with First Manhattan and

    4. Premarket Gainers / Losers


      Thu, 3 Apr 2014

      Gainers: AMRS +14% . CYTR +10% . MNGA +7% . CPRX +7% . CTRP +5% . Losers: SGOC -32% . BGMD -18% . LQDT -13% . APPY -12% . BKS -9% . [[PBR-A]] -6% . VVUS -5% . Post your comment!

    5. Vivus gets slapped


      Thu, 3 Apr 2014

      Piper Jaffray downgrades Vivus ( VVUS ) to Underweight with a PT of $3.00. Shares are down 5% to $5.85 premarket on 107K shares. Consensus estimates for Q1

    6. Can Stendra Cure Vivus


      Tue, 1 Apr 2014

      near 52 week lows? Investors in Vivus ( VVUS ) certainly hope so, and there are ..... erectile dysfunction drug Stendra. Vivus and its marketing partner Auxilliam ..... sales could really get impressive. Vivus had put a lot of hope into the anti

    7. Arena - Scripts, Ads, Sales Reps


      Fri, 28 Mar 2014

      television ads will be the first from the either Arena or Vivus ( VVUS ) since Belviq and Qsymia entered the market. The prescription ..... its challenges. Qsymia, the anti-obesity drug from Vivus , has been on the market well over a year and has stalled

    8. Vivus : Shares Are Oversold, Pressure Is On To Secure A Commercial Partner And Drive Market Penetration


      Wed, 26 Mar 2014

      Investor : Company Description: Vivus ( VVUS ) is a Mountain View, CA based biopharma ..... and the subsequent FDA withdrawal , Vivus was required to conduct three large ..... in certified retail pharmacies. Vivus second product is Avanafil, which

    9. Arena Down With Overall Market - Sales Data No Help


      Mon, 17 Mar 2014

      By Spencer Osborne : As we head toward the end of the first quarter, and the fiscal year end for Arena's ( ARNA ) marketing partner Eisai ( OTCPK:ESALY ), it is appropriate to assess where we are for both companies in terms of the sales for the anti-obesity drug Belviq. As it happens, this week's

    10. Veeva: Irrefutable Proof Of TAM Overstatements, CRM Seat Saturation, Drastic Growth Deceleration, And Highly Dubious Sell-Side Coverage


      Thu, 13 Mar 2014

      By Suhail Capital : " Vi Veri Veniversum Vivus Vici " Veeva: Irrefutable Proof of TAM Overstatements, Pharma Rep Seat Saturation, Drastic Growth Deceleration, Opaque Disclosures

    « Prev12345Next »
    Content Partners